WallStSmart

Energy Transfer LP (ET)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Energy Transfer LP generates 213% more annual revenue ($92.29B vs $29.44B). GILD leads profitability with a 28.9% profit margin vs 4.7%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).

ET

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 5.5Value: 8.7Quality: 5.0

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 8.7Quality: 5.8
Piotroski: 6/9Altman Z: 1.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ETUndervalued (+87.7%)

Margin of Safety

+87.7%

Fair Value

$148.16

Current Price

$19.34

$128.82 discount

UndervaluedFair: $148.16Overvalued
GILDUndervalued (+44.2%)

Margin of Safety

+44.2%

Fair Value

$235.52

Current Price

$131.33

$104.19 discount

UndervaluedFair: $235.52Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ET6 strengths · Avg: 8.5/10
Revenue GrowthGrowth
32.1%10/10

Revenue surging 32.1% year-over-year

Market CapQuality
$68.55B9/10

Large-cap with strong market position

PEG RatioValuation
0.738/10

Growing faster than its price suggests

P/E RatioValuation
16.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.38B8/10

Generating 3.4B in free cash flow

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$166.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

ET2 concerns · Avg: 2.5/10
Profit MarginProfitability
4.7%3/10

4.7% margin — thin

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

GILD2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.814/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ET

The strongest argument for ET centers on Revenue Growth, Market Cap, PEG Ratio. Revenue growth of 32.1% demonstrates continued momentum. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : ET

The primary concerns for ET are Profit Margin, EPS Growth. Thin 4.7% margins leave little buffer for downturns.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

ET profiles as a hypergrowth stock while GILD is a value play — different risk/reward profiles.

ET carries more volatility with a beta of 0.57 — expect wider price swings.

ET is growing revenue faster at 32.1% — sustainability is the question.

ET generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

GILD scores higher overall (72/100 vs 62/100), backed by strong 28.9% margins. ET offers better value entry with a 87.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Energy Transfer LP

ENERGY · OIL & GAS MIDSTREAM · USA

Energy Transfer LP offers energy related services. The company is headquartered in Dallas, Texas.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?